AstraZeneca Pharma India receives no objection for Durvalumab

Durvalumab in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer

Aurobindo Pharma gets VAI classification from USFDA for Telangana plant

Company's Unit - IX, an API intermediate facility situated at Sangareddy District, Telangana, has now been classified as Voluntary Action Indicated

Johnson & Johnson appoints Dr. John Reed as EVP, Pharmaceuticals, R&D

Sun Pharma Announces USFDA Approval for Generic Lenalidomide Capsules

The respective product approval is based on Revlimid Capsules, 5mg, 10mg, 15mg, 25mg and 2.5mg, 20mg as a reference product

Glenmark Pharma reports Q3 FY 2022-23 revenue growth of 9.2%; PAT growth of 21.3%

Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY

Aurobindo Pharma Q3 FY23 net profit down 18.7% at Rs 491 Crores

Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.

JB Pharma records revenue growth of 32% to Rs. 793 Cr in Q3 FY23

Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%

IOL Chemicals and Pharmaceuticals Q3 FY23 income down 6%

The company completed paracetamol capacity expansion by 1,800 MTPA and the company is now focusing on frugal manufacturing practices to reduce raw material cost and expand margins

Alembic Pharmaceuticals Q3 FY23 revenue up 19% to Rs. 1,509 Cr

Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore

Bal Pharma posts Q3 FY2023 profit at Rs. 59.16 lakhs

The company has reported total income of Rs.77.0791 crores during the period ended December 31, 2022 as compared to Rs.69.9191 crores during the period ended December 31, 2021.